Research programme: intranasal hepatitis B vaccine - BlueWillow Biologics
Alternative Names: NB-007; Transmucosal hepatitis B vaccine - BlueWillow BiologicsLatest Information Update: 09 May 2018
At a glance
- Originator University of Michigan
- Developer BlueWillow Biologics; University of Michigan
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Intranasal, Drops)
- 22 Apr 2010 Preclinical development is ongoing in USA